Cargando…

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers

Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Teyssonneau, Diego, Thiery-Vuillemin, Antoine, Dariane, Charles, Barret, Eric, Beauval, Jean-Baptiste, Brureau, Laurent, Créhange, Gilles, Fiard, Gaëlle, Fromont, Gaëlle, Gauthé, Mathieu, Ruffion, Alain, Renard-Penna, Raphaële, Mathieu, Romain, Sargos, Paul, Rouprêt, Morgan, Ploussard, Guillaume, Roubaud, Guilhem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952857/
https://www.ncbi.nlm.nih.gov/pubmed/35330059
http://dx.doi.org/10.3390/jcm11061734
_version_ 1784675720521318400
author Teyssonneau, Diego
Thiery-Vuillemin, Antoine
Dariane, Charles
Barret, Eric
Beauval, Jean-Baptiste
Brureau, Laurent
Créhange, Gilles
Fiard, Gaëlle
Fromont, Gaëlle
Gauthé, Mathieu
Ruffion, Alain
Renard-Penna, Raphaële
Mathieu, Romain
Sargos, Paul
Rouprêt, Morgan
Ploussard, Guillaume
Roubaud, Guilhem
author_facet Teyssonneau, Diego
Thiery-Vuillemin, Antoine
Dariane, Charles
Barret, Eric
Beauval, Jean-Baptiste
Brureau, Laurent
Créhange, Gilles
Fiard, Gaëlle
Fromont, Gaëlle
Gauthé, Mathieu
Ruffion, Alain
Renard-Penna, Raphaële
Mathieu, Romain
Sargos, Paul
Rouprêt, Morgan
Ploussard, Guillaume
Roubaud, Guilhem
author_sort Teyssonneau, Diego
collection PubMed
description Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2. While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations.
format Online
Article
Text
id pubmed-8952857
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89528572022-03-26 PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers Teyssonneau, Diego Thiery-Vuillemin, Antoine Dariane, Charles Barret, Eric Beauval, Jean-Baptiste Brureau, Laurent Créhange, Gilles Fiard, Gaëlle Fromont, Gaëlle Gauthé, Mathieu Ruffion, Alain Renard-Penna, Raphaële Mathieu, Romain Sargos, Paul Rouprêt, Morgan Ploussard, Guillaume Roubaud, Guilhem J Clin Med Review Despite recent improvements in survival, metastatic castration-resistant prostate cancers (mCRPCs) remain lethal. Alterations in genes involved in the homologous recombination repair (HRR) pathway are associated with poor prognosis. Poly-ADP-ribose polymerase (PARP) inhibitors (PARPis) have demonstrated anti-tumoral effects by synthetic lethality in patients with mCRPCs harboring HRR gene alterations, in particular BRCA2. While both olaparib and rucaparib have obtained government approvals for use, the selection of eligible patients as well as the prescription of these treatments within the clinical urology community are challenging. This review proposes a brief review of the rationale and outcomes of PARPi treatment, then a pragmatic vision of PARPi use in terms of prescription and the selection of patients based on molecular screening, which can involve potential genetic counseling in the case of associated germinal alterations. MDPI 2022-03-21 /pmc/articles/PMC8952857/ /pubmed/35330059 http://dx.doi.org/10.3390/jcm11061734 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Teyssonneau, Diego
Thiery-Vuillemin, Antoine
Dariane, Charles
Barret, Eric
Beauval, Jean-Baptiste
Brureau, Laurent
Créhange, Gilles
Fiard, Gaëlle
Fromont, Gaëlle
Gauthé, Mathieu
Ruffion, Alain
Renard-Penna, Raphaële
Mathieu, Romain
Sargos, Paul
Rouprêt, Morgan
Ploussard, Guillaume
Roubaud, Guilhem
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
title PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
title_full PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
title_fullStr PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
title_full_unstemmed PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
title_short PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
title_sort parp inhibitors as monotherapy in daily practice for advanced prostate cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952857/
https://www.ncbi.nlm.nih.gov/pubmed/35330059
http://dx.doi.org/10.3390/jcm11061734
work_keys_str_mv AT teyssonneaudiego parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT thieryvuilleminantoine parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT darianecharles parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT barreteric parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT beauvaljeanbaptiste parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT brureaulaurent parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT crehangegilles parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT fiardgaelle parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT fromontgaelle parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT gauthemathieu parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT ruffionalain parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT renardpennaraphaele parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT mathieuromain parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT sargospaul parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT roupretmorgan parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT ploussardguillaume parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT roubaudguilhem parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers
AT parpinhibitorsasmonotherapyindailypracticeforadvancedprostatecancers